Vascular biology and bone formation: Hints from HIF

Dwight A. Towler
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
https://digitalcommons.wustl.edu/open_access_pubs/1595

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
In this issue of the JCI, Wang, Clemens, and colleagues demonstrate that hypoxia-inducible factor \( \alpha \) (HIF\(\alpha\)) signaling in bone-building osteoblasts is central to the coupling of angiogenesis and long bone development in mice (see the related article beginning on page 1616). They show that bone formation controlled by osteoblast HIF\(\alpha\) signaling is not cell autonomous but is coupled to skeletal angiogenesis dependent upon VEGF signaling. Thus, strategies that promote HIF\(\alpha\) signaling in osteoblasts may augment bone formation and accelerate fracture repair.

Tremendous unmet clinical needs exist in musculoskeletal medicine. The direct costs of musculoskeletal diseases in the United States are well over $100 billion per annum (1). Osteoporosis and osteoarthritis are recognized as common and clinically important, but other serious skeletal diseases also afflict our populace. In the setting of type 2 diabetes mellitus (T2DM), lower-extremity musculoskeletal disease is prevalent, costly, and exceedingly difficult to manage, with fracture, arthropathy, ischemia, ulcer, and infection commonly confronting patients and clinicians. The total costs associated with lower-extremity amputation in T2DM alone are greater than the combined costs of treating fatal and nonfatal myocardial infarction associated with T2DM (2). Stage-specific and disease-specific strategies are necessary to safely promote bone formation in individuals with: (a) underlying vasculopathies, such as those associated with diabetes or renal failure; (b) underlying malignancy of any sort; (c) extant osteoporosis that has removed trabecular templates for bone apposition; (d) osteoporosis in the setting of childhood growth and open epiphyses; and (e) drug- or coagulopathy-related disorders that cause avascular necrosis.

In this issue of the JCI, the study by Wang et al. (3) affords us a better understanding of the mechanisms coupling bone and vascular physiology, providing insights useful for devising novel strategies to address the mounting unmet needs in orthopedic medicine. The vasculature provides: (a) a sustentacular niche and source of adult mesenchymal stem cells, including osteoprogenitors; (b) the organizational and rate-limiting “point of reference” for Haversian bone formation; and (c) the conduit for calcium, phosphate, hematopoietic, and nutrient supply necessary for mineralization and calcium mobilization (4–11). We know precious little about how the vasculature integrates and conveys signals during skeletogenesis. However, VEGF (9) has emerged as the prototypic osteogenic-angiogenic coupling factor (10). The VEGF gene encodes a secreted polypeptide globally required for vasculogenesis and angiogenesis (11). Bioactivity is modulated by VEGF gene expression — and differential splicing that generates three unique gene products — with signals transduced via specific VEGF receptor tyrosine kinases (9). The name “VEGF” belies its contributions to osteoblast ontology, chondrocyte physiology, and osteoclast formation (10). VEGF signaling is tightly regulated in bone, coupled to morphogenetic, metabolic, inflammatory, and mechanical cues that control mineral metabolism. In addition to regulating the expansion and survival of mesenchymal progenitors (Figure 1 and below), signals provided by VEGFR2 mediates angiogenic cross-talk with TNF receptor 2 (TNFR2) (12), critical for postnatal defense against limb ischemia (13). Given the contributions of bone-vascular interactions to all aspects of bone biology, our limited understanding of this important physiology impedes development of novel bone anabolic therapies.

New hints from HIF

In their current study, Wang, Clemens, and colleagues (3) significantly advance our understanding of bone-vascular coupling by establishing the critical role for osteoblast hypoxia-inducible factor 1\(\alpha\) (HIF-1\(\alpha\)) and HIF-2\(\alpha\) in bone formation (Figure 1). As recently reviewed (14), HIFs are components of heterodimeric, hypoxia-activated transcription factor complexes that bind to well-characterized DNA cognates called hypoxia-response elements, activating the expression of genes such as VEGF and erythropoietin that can improve tissue oxygen delivery (15). Dependent upon cellular context, HIF-1\(\alpha\) and HIF-2\(\alpha\) may or may not exhibit functional redundancy (14). The Clemens group first showed that osteoblasts express all necessary components of the oxygen-sensing pathway in addition to HIF-1\(\alpha\) and HIF-2\(\alpha\) (herein collectively referred to as HIF\(\alpha\)). These components include the oxygen-dependent prolyl hydroxylases (PHDs) that “tag” HIF\(\alpha\) for recognition by the E3 ubiquitin ligase von Hippel–Lindau protein (pVHL) and pVHL itself, necessary for HIF\(\alpha\) proteosomal degradation (3) (Figure 1). Moreover, the authors demonstrate hypoxia-dependent nuclear accumulation of HIF\(\alpha\) and concomitant upregulation of VEGF expression, indicating intact oxygen-sensing functions in osteoblasts. To evaluate the biological importance of osteoblast HIF signaling in vivo, the authors used Cre-lox technology; they implemented the bone-specific human osteocalcin promoter as a delivery module for Cre recombinase expression in mice possessing floxed Vhl
alleles. This strategy abrogates pVHL accumulation in mature osteoblasts (3). In this conditional knockout, denoted ΔVhl, osteoblast accumulation of both HIF-1α and HIF-2α was induced due to the absence of pVHL-dependent degradation (Figure 1). The in vivo effects on long bone formation were remarkable; bone volume/tissue volume (BV/TV) increased by 70% with osteoblast-specific induction of HIF-1α subunits. Detailed histomorphometry revealed very early postnatal increases in trabecular osteoblast numbers during long bone modeling — numbers that “normalized” once a new steady state of high bone mass was achieved in ΔVhl mice (3). In culture, osteoblasts possessing floxed Vhl alleles also upregulated HIFα when transduced with an adenoviral Cre vector — with concomitant induction of VEGF. HIFα induction did not alter cultured osteoblast proliferation rate, apoptotic rate, matrix synthetic activity, or mineral deposition ex vivo; thus, the bone anabolic actions of osteoblast HIFα induction observed in vivo were not cell autonomous. Bone histomorphometry and serum biochemistries showed no decrements in bone-resorbing osteoclast numbers or activity, excluding overt contributions of osteoclast insufficiency to increased BV/TV in ΔVhl mice. However, a profound increase in bone vascularity was observed for the ΔVhl mice (3). Moreover, a massive increase in capillary sprouting was exhibited by ΔVhl long bones maintained in organ culture (3). Angiogenic responses were dependent upon paracrine VEGF actions, since: (a) VEGF-neutralizing antibody abrogated sprouting; and (b) skeletal production of VEGF mRNA was increased in ΔVhl mice without changes in circulating VEGF. Relationships to HIFα-dependent angiogenesis and bone formation were further confirmed using mice in which Hif1a was conditionally knocked out in osteoblasts (ΔHif1a mice). Bone volume and vascularity were reduced in ΔHif1a mice, with reductions partially offset by compensatory HIF-2α expression. The overlapping redundancy of the latter was diligently demonstrated using a third mouse model, Vhl gene deletion in ΔHif1a mice; these ΔVhl/ΔHif1a mice exhibited markedly increased HIF-2α protein accumulation, with concomitant restoration of bone volume and angiogenesis (3). Thus, the authors conclude that osteoblast HIFα signaling is a central component of rate-limiting, osteogenic-angiogenic coupling that controls long bone formation. This coupling occurs via...
mechanisms that are not cell autonomous and that utilize paracrine VEGF angiogenic signals to expand osteoblast numbers during long bone development (3).

Angiogenesis and osteoblast ontology

How, then, might the angiogenic response and osteogenic-angiogenic coupling increase osteoblast numbers and provide the massive marrow bone formation observed (3)? Recently, several groups have identified the microvascular smooth muscle cell, the pericyte, as an important osteoprogenitor (16–24) (Figure 1). Demer, Canfield, and colleagues have shown that the pericyte exhibits multipotentiality, capable of osteogenic, chondrogenic, adipogenic, and SMC differentiation (17, 18). Molecularly, pericytes express early features of the VSMC lineage, including smooth muscle 22 kDa (SM22), α-SMC, and species-specific gangliosides demarcated by the 3G5 monoclonal antibody (17, 19). Anatomically, the pericyte is intimately juxtaposed to the endothelial capillary network. In the marrow microenvironment, the bone marrow stromal cell exhibits the histoanatomic characteristics of the pericyte (16). Thus, from this perspective the bone marrow stromal cell—the osteoprogenitor—can be viewed as a tissue-specific pericyte.

What is the ontology of the vascular pericyte? Cossu and colleagues provide data suggesting that the mesoangioblast (20), a vessel-associated mesenchymal stem cell with the capacity to differentiate into cells of endothelial and VSMC lineages, might be the source of pericytes. Studies of differentiating murine ES cells confirm the existence of a highly plastic, VEGFR2+ endothelial-SMC progenitor—a mesenchymal stem cell that can give rise to mineralizing osteoblasts in culture via pericytic SMC lineage (23). Skeletal osteoblasts can and do arise from the pericyte cell lineage in vivo; SM22-positive and α-SMC-positive cells “coregister” with preosteoblasts identified using Col3.6-GFP reporter mice following induction of de novo osteogenesis (24). Thus, concomitant with angiogenic sprouting, VEGF/VEGFR2 signaling is posited to expand the potential osteoprogenitor pool via the pericyte intermediate (Figure 1). However, until better pericyte lineage markers are developed, or the effects of HIFα manipulation that promotes robust angiogenesis and bone formation via nonendochondral mechanisms—upregulates both HIF-1α and VEGF (29). Thus, it is tempting to speculate that the differences observed by Wang et al. (3) arise due to differences in the rate-limiting stimuli that control osteogenic-angiogenic coupling in calvarial versus long bone development. For the moment, however, the precise reasons for the differences observed between long bone and calvarial bone formation following Vhl deletion remain to be determined.

Future directions

Many questions remain to be answered. Although HIFα clearly regulates osteogenic-angiogenic interactions necessary for bone formation, other secreted molecules in addition to VEGF, such TNF-α (6, 12, 13) and FGF2 (5, 27, 28), might contribute to this coupling. Potential contributions of paracrine TNF-α signaling—an important activator of TNFR2-VEGFR2 cross-talk (12, 13) and bone formation (6) have yet to be detailed. Should administration of bevacizumab, a clinically useful inhibitory antibody to VEGF (30), be shown to abrogate the bone anabolic effects of osteoblast HIFα, this would provide pharmacologic evidence that paracrine VEGF signals are nonredundant in osteogenic-angiogenic coupling. Moreover, since VEGF induces the production of bone morphogenetic protein (BMP) by endothelial cells (5), the consequences of inactivating endothelial BMP expression would help support the evolving working model (Figure 1). The mechanisms that punctuate feed-forward osteogenic-angiogenic coupling are not known but clearly exist, since osteoblast numbers and bone formation quickly normalizes postnatally at a higher bone mass (3). The “osteostar” mechanism responsible for this physiologic response will be extremely important to delineate—and may be metabolically as well as mechanically determined. It may be possible to selectively augment skeletal HIF-1α action—potentially by inhibiting specific PHDs—as one strategy to promote bone formation and fracture healing. It will be important to evaluate how the material and geometric properties of bone manipulated via the HIFα pathway impact bone strength. Finally, better markers are required to unambiguously characterize precursor-product relationships in the mesoangioblast/pericyte/osteoblast lineage; such ontology is likely to contribute to changes in trabecular bone mass dependent upon osteoblast HIFα signaling (16, 18). All in all, novel and very important biological principles emerge from the current study (3), i.e., that osteogenesis and angiogenesis are functionally coupled in the marrow microenvironment by osteoblast HIFα signaling. Thus, in addition to osteoblast and osteoclast lineages, the contributions of endothelial cell precursors and their progeny (Figure 1) must be considered in robust studies of bone formation and skeletal homeostasis.

Acknowledgments

The author is supported by NIH grants HL69229, HL81138, AR43731, and the Barnes-Jewish Hospital Foundation.

Address correspondence to: Dwight A. Towler, Washington University School of Medicine, Barnes-Jewish North Campus Box 8301, 660 South Euclid Avenue, St. Louis, Missouri 63110, USA. Phone: (314) 454-7434; Fax: (314) 454-8434; E-mail: dtowler@im.wustl.edu.

Sizing up sialic acid in glomerular disease

Susan E. Quaggin
The Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Division of Nephrology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada.

A new study by Galeano and colleagues in this issue of the JCI reports the first glomerular disease caused by a genetic defect in sialic acid biosynthesis (see the related article beginning on page 1585). Mice that harbor mutations in the Gne/Mnk gene produce lower amounts of sialic acid, suffer from hematuria, proteinuria, and structural defects in the glomerulus and die within days after birth. Remarkably, the lesion can be reversed through dietary addition of N-acetylmannosamine, a sialic acid precursor, raising the intriguing possibility that this approach might have therapeutic benefit in patients with glomerular disease.

In this issue of the JCI, Galeano, Huizing, and colleagues (1) describe kidney defects in knockin mice that harbor the M712T muta-

tion in the gene encoding the key bifunctional enzyme of sialic acid biosynthesis — uridine diphaspho-N-acetylglucosamine 2-epimerase/N-acetylmannosamine (ManNAc) kinase (GNE/MNK) (Gne exon 1 (2, 3), in mice). In patients, mutations in the GNE gene result in the autosomal recessive neuromuscular disorder, hereditary inclusion body myopathy (HIBM; MIM 600737) that presents late in life as a slowly progressive myopathy (4, 5). The N-acetylglucosamine/ManNAc enzyme is ubiquitously expressed and catalyzes the first rate-limiting steps in the biosynthesis of sialic acid (Figure 1). 5-N-acetylenuraminic acid (Neu5Ac) is the most plentiful mammalian sialic acid and is the terminal sugar on glycoconjugates, where it functions in cellular interactions and signaling. Muscle fibers from patients with HIBM exhibit reduced sialylation of proteins, which is believed to underlie disease pathogenesis. Currently, there is no effective therapy for this disorder.

In the current study (1), the investigators sought to develop a mouse model to test whether dietary supplementation of sialic acid or its precursor, ManNAc, could reverse the hyposialylation defect observed in patients. Standard Gne knockout mice die in utero (6). To overcome this early mortality, the authors generated a mouse carrying one of the most common non-lesional mutations observed in patients with HIBM. Surprisingly, mice homozygous for

nonstandard abbreviations used: Gne, uridine diphaspho-N-acetylglucosamine 2-epimerase; HIBM, hereditary inclusion body myopathy; ManNAc, N-acetylmannosamine; Mnk, ManNAc kinase; Pc, podoca-

lysin; SD, slit diaphragm.

Conflict of interest: The author is the recipient of a research grant from Genentech and is a scientific consultant for Genentech.


Sizing up sialic acid in glomerular disease

Susan E. Quaggin
The Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Division of Nephrology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada.

A new study by Galeano and colleagues in this issue of the JCI reports the first glomerular disease caused by a genetic defect in sialic acid biosynthesis (see the related article beginning on page 1585). Mice that harbor mutations in the Gne/Mnk gene produce lower amounts of sialic acid, suffer from hematuria, proteinuria, and structural defects in the glomerulus and die within days after birth. Remarkably, the lesion can be reversed through dietary addition of N-acetylmannosamine, a sialic acid precursor, raising the intriguing possibility that this approach might have therapeutic benefit in patients with glomerular disease.

In this issue of the JCI, Galeano, Huizing, and colleagues (1) describe kidney defects in knockin mice that harbor the M712T muta-

tion in the gene encoding the key bifunctional enzyme of sialic acid biosynthesis — uridine diphaspho-N-acetylglucosamine 2-epimerase/N-acetylmannosamine (ManNAc) kinase (GNE/MNK) (Gne exon 1 (2, 3), in mice). In patients, mutations in the GNE gene result in the autosomal recessive neuromuscular disorder, hereditary inclusion body myopathy (HIBM; MIM 600737) that presents late in life as a slowly progressive myopathy (4, 5). The N-acetylglucosamine/ManNAc enzyme is ubiquitously expressed and catalyzes the first rate-limiting steps in the biosynthesis of sialic acid (Figure 1). 5-N-acetylenuraminic acid (Neu5Ac) is the most plentiful mammalian sialic acid and is the terminal sugar on glycoconjugates, where it functions in cellular interactions and signaling. Muscle fibers from patients with HIBM exhibit reduced sialylation of proteins, which is believed to underlie disease pathogenesis. Currently, there is no effective therapy for this disorder.

In the current study (1), the investigators sought to develop a mouse model to test whether dietary supplementation of sialic acid or its precursor, ManNAc, could reverse the hyposialylation defect observed in patients. Standard Gne knockout mice die in utero (6). To overcome this early mortality, the authors generated a mouse carrying one of the most common non-lesional mutations observed in patients with HIBM. Surprisingly, mice homozygous for

nonstandard abbreviations used: Gne, uridine diphaspho-N-acetylglucosamine 2-epimerase; HIBM, hereditary inclusion body myopathy; ManNAc, N-acetylmannosamine; Mnk, ManNAc kinase; Pc, podoca-

lysin; SD, slit diaphragm.

Conflict of interest: The author is the recipient of a research grant from Genentech and is a scientific consultant for Genentech.


Sizing up sialic acid in glomerular disease

Susan E. Quaggin
The Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Division of Nephrology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada.

A new study by Galeano and colleagues in this issue of the JCI reports the first glomerular disease caused by a genetic defect in sialic acid biosynthesis (see the related article beginning on page 1585). Mice that harbor mutations in the Gne/Mnk gene produce lower amounts of sialic acid, suffer from hematuria, proteinuria, and structural defects in the glomerulus and die within days after birth. Remarkably, the lesion can be reversed through dietary addition of N-acetylmannosamine, a sialic acid precursor, raising the intriguing possibility that this approach might have therapeutic benefit in patients with glomerular disease.

In this issue of the JCI, Galeano, Huizing, and colleagues (1) describe kidney defects in knockin mice that harbor the M712T muta-